By Billy Candra 
A groundbreaking, federally funded clinical trial has achieved a significant breakthrough in breast cancer care, demonstrating the feasibility of identifying survivors at heightened risk of relapse due to dormant cancer cells and effectively neutralizing these "sleeper cells" using repurposed, existing medications. This landmark research, spearheaded by scientists from the Abramson Cancer Center at the University of Pennsylvania and Penn’s Perelman School of Medicine, was formally published today in the prestigious journal Nature Medicine, marking a potential paradigm shift in post-treatment cancer management.
The journey of breast cancer survival, while consistently improving due to relentless advancements in early detection and therapeutic interventions, remains shadowed by the persistent threat of recurrence. When breast cancer relapses, often years or even decades after initial successful treatment, it typically enters an incurable metastatic stage. This grim reality affects approximately 30 percent of women and men who have previously battled the disease, consigning them to a future of continuous, often debilitating, and ultimately indefinite treatment regimens that can manage but not eradicate the re-emergent cancer. The nature of this recurrence varies significantly; aggressive subtypes like triple-negative and HER2-positive breast cancers often resurface within a few years, while hormone-receptor-positive (ER+) cancers can lie dormant for extended periods, sometimes for more than two decades, before reactivating. Until now, oncologists lacked a reliable, real-time method to pinpoint which breast cancer survivors harbored these insidious dormant cells and, crucially, had no targeted intervention to prevent the often-fatal relapse.
The Phase II randomized clinical trial, involving 51 breast cancer survivors, represents a monumental leap forward. The study successfully demonstrated that existing, repurposed drugs were capable of clearing dormant tumor cells from an impressive 80 percent of the participants. The clinical outcomes were equally compelling: a three-year survival rate without any disease recurrence soared above 90 percent for patients who received monotherapy with one of the study drugs, and an extraordinary 100 percent recurrence-free survival rate for those who received the combination therapy of both study drugs. These figures offer a beacon of hope for millions globally living with the anxiety of potential relapse.
"The lingering fear of cancer returning is something that hangs over many breast cancer survivors after they celebrate the end of treatment," stated principal investigator Angela DeMichele, MD, MSCE, FASCO, the Mariann T. and Robert J. MacDonald Professor in Breast Cancer Research. Her sentiments resonate deeply with patients worldwide. "Right now, we just don’t know when or if someone’s cancer will come back — that’s the problem we set out to solve. Our study shows that preventing recurrence by monitoring and targeting dormant tumor cells is a strategy that holds real promise, and I hope it ignites more research in this area." Dr. DeMichele’s emphasis on proactive intervention underscores a fundamental shift from a reactive "wait and see" approach to a preventative strategy.
The Persistent Threat of Recurrence: A Global Health Challenge
Breast cancer is the most common cancer among women globally, accounting for nearly 2.3 million new cases in 2020 alone, and remains a leading cause of cancer-related deaths. While significant progress in screening, surgery, chemotherapy, radiation, and targeted therapies has dramatically improved five-year survival rates, particularly in developed nations, the specter of recurrence continues to be a formidable challenge. For instance, while localized breast cancer has a five-year survival rate exceeding 99%, and regional cancer around 86%, metastatic breast cancer, which often results from recurrence, has a five-year survival rate of only 30%. This stark contrast highlights the critical need for interventions that can prevent the transition from dormant disease to metastatic spread. The ability to identify and eliminate minimal residual disease (MRD) before it manifests clinically could fundamentally alter the natural history of breast cancer for many survivors.
Unveiling the "Sleeper Cells": A Scientific Frontier
The study builds upon years of foundational research into the perplexing phenomenon of cancer dormancy. These so-called "sleeper cells," also referred to as minimal residual disease (MRD), are tumor cells that survive initial treatments but remain in a non-proliferative, quiescent state. Unlike actively growing cancer cells, dormant cells do not divide rapidly, making them resistant to conventional chemotherapies that target dividing cells. Furthermore, because they are not "active" and can be scattered throughout the body, often in distant sites like the bone marrow, they do not register on standard imaging tests such as mammograms, CT scans, or PET scans, which are primarily designed to detect metabolically active or growing lesions. This inherent invisibility has made them notoriously difficult to detect and, consequently, to treat.
Once these sleeper cells begin to expand and circulate in the bloodstream, they can lead to the widespread dissemination of metastatic breast cancer. Patients identified with MRD, even if asymptomatic, are known to have a significantly higher likelihood of experiencing breast cancer recurrence and often face decreased overall survival rates. This understanding formed the critical scientific premise for the current trial.
Lewis Chodosh, MD, PhD, chair of Cancer Biology and senior author of the study, has been at the forefront of this research for years, having previously led investigations to identify the specific molecular pathways that enable dormant tumor cells to persist in patients for decades. "Our research shows that this sleeper phase represents a unique window of opportunity to intervene and eradicate these dormant tumor cells before they have the chance to come back as aggressive, metastatic disease," Chodosh explained. He added a particularly intriguing insight: "Surprisingly, we’ve found that certain drugs that don’t work against actively growing cancers can be very effective against these sleeper cells. This tells us that the biology of dormant tumor cells is very different from active cancer cells, requiring a distinct therapeutic strategy." This revelation underscores the need for targeted approaches that specifically address the unique biology of quiescent cancer cells, rather than simply repurposing drugs designed for proliferating tumors.
Preclinical Foundation: Decoding Dormancy Pathways
The preclinical segment of the latest research publication, meticulously conducted by Dr. Chodosh’s team, involved a series of intricate experiments in mouse models. These studies were designed to unravel the fundamental mechanisms that allow tumor cells to remain dormant and, crucially, to identify vulnerabilities that could be therapeutically exploited. Their findings were pivotal, revealing that two distinct pathways, autophagy and mTOR signaling, were key to the tumor cells’ ability to maintain their dormant state. Autophagy is a cellular process involving the degradation and recycling of cellular components, essential for cell survival under stress, while mTOR signaling plays a central role in regulating cell growth, proliferation, and survival.
By targeting these specific pathways, the researchers identified two existing drugs, already approved by the U.S. Food and Drug Administration (FDA) for treating other conditions, that could effectively clear MRD in mice. The successful eradication of these dormant cells in the animal models directly translated into longer survival without cancer recurrence, providing robust preclinical validation for their subsequent human trial. The use of FDA-approved drugs is a critical advantage, as it significantly accelerates the translational process, leveraging known safety profiles and manufacturing infrastructure, thus potentially bringing these therapies to patients much faster than developing entirely new compounds.
The CLEVER Trial: Translating Science into Original Clinical Trials
The human clinical trial, named CLEVER, was meticulously designed to translate these preclinical insights into a tangible patient benefit. Dr. DeMichele’s team initiated the process by enrolling breast cancer survivors who had completed their primary treatment within the last five years and had clear scans, indicating no active disease. These participants were initially recruited into a screening study specifically designed to detect dormant tumor cells in their bone marrow – a known sanctuary site for MRD. This innovative screening step is a critical component of the strategy, acting as a predictive biomarker to identify high-risk individuals.
If dormant tumor cells were detected in the bone marrow, patients became eligible to enroll in the Phase II CLEVER clinical trial. Participants were then randomized to receive six cycles of either monotherapy with one of the two repurposed study drugs or a combination therapy utilizing both drugs. The treatment proved remarkably effective, clearing dormant tumor cells in the majority of patients within six to twelve months. Following a median follow-up period of 42 months (3.5 years), only two patients in the entire study cohort experienced a cancer recurrence, underscoring the profound impact of this preventative intervention.
"We want to be able to give patients a better option than ‘wait and see’ after they complete breast cancer treatment," Dr. DeMichele emphasized, highlighting the emotional and psychological toll the uncertainty of recurrence takes on survivors. "We’re encouraged by these results that we’re on the right track." This proactive approach represents a significant departure from current clinical practice, offering a tangible strategy to alleviate the pervasive anxiety of relapse.
A New Paradigm: Implications for Breast Cancer Management
The findings of the CLEVER trial carry profound implications for the future of breast cancer management. This research suggests a potential paradigm shift from solely treating active, symptomatic cancer to proactively intervening when cancer cells are "sleeping." This approach could transform the lives of millions of survivors by offering a concrete strategy to prevent recurrence, thereby improving not only survival rates but also the overall quality of life by mitigating the constant fear of the disease returning.
The ability to identify and target MRD represents a crucial step towards personalized medicine in oncology. By pinpointing individuals with dormant cells, clinicians could administer highly specific, preventative treatments only to those who truly need them, avoiding unnecessary therapies for low-risk individuals. This targeted approach minimizes side effects and optimizes resource allocation. Furthermore, the success of repurposed drugs highlights the immense value of re-evaluating existing pharmacopeia for new applications, potentially offering faster, more cost-effective solutions to complex medical challenges. This strategy could reduce the enormous financial burden associated with developing new drugs and expedite patient access to life-saving treatments.
Funding and Collaborative Endeavor
This pivotal research was made possible through a robust foundation of funding from critical governmental and philanthropic organizations. Major contributions were provided by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), through grant R01CA208273, and the Department of Defense (DoD) through grant BC160784. This federal support underscores the national importance and strategic investment in advancing cancer research.
Additional vital support came from a consortium of philanthropic partners, including the V Foundation for Cancer Research, the Breast Cancer Research Foundation (BCRF), QVC "Shoes on Sale," the Avon Foundation, and the Raynier Institute & Foundation, alongside numerous generous individual philanthropic donations. This diverse funding base highlights the collaborative spirit required to tackle complex diseases like cancer, bringing together governmental agencies, non-profit organizations, and private citizens in a shared mission. Dr. DeMichele had previously presented interim outcomes data from the study at the European Society for Medical Oncology (ESMO) Congress 2023, generating early excitement within the global oncology community.
The Road Ahead: Larger Trials and Broader Impact
While the results of the CLEVER Phase II trial are undeniably promising, the scientific process mandates further rigorous validation. To confirm and expand upon these initial findings, the Penn Medicine team is already actively enrolling patients in two larger, ongoing studies: the Phase II ABBY clinical trial and the Phase II PALAVY clinical trial. These trials are designed to include a greater number of participants and are available at several leading cancer centers across the country, aiming to replicate the success of CLEVER in a broader and more diverse patient population. The expansion to multiple sites also facilitates wider participation and data collection, strengthening the statistical power and generalizability of the results.
The long-term vision extends beyond breast cancer. The understanding of cancer dormancy and the strategies to target it could potentially be applied to other solid tumor types where recurrence from minimal residual disease remains a significant challenge, such as lung, colon, or ovarian cancers. This research not only offers immediate hope for breast cancer survivors but also paves the way for a new frontier in oncology, focusing on early intervention and disease prevention rather than just treatment of active disease. Patients interested in learning more about these or other breast cancer clinical trials at Penn Medicine are encouraged to contact [email protected]. This breakthrough represents a monumental stride towards a future where breast cancer recurrence is not an inevitable threat but a preventable outcome.
